Karuna Three-For-Three As Another KarXT Schizophrenia Trial Hits Primary Endpoint
Executive Summary
The company is on track for a mid-2023 FDA filing, while executives suggested that they would likely pursue partnership for commercialization of the drug in Europe.
You may also be interested in...
AbbVie Says Buying Spree Will Add R&D Heft Needed For Long-Term Growth
Buying Cerevel six days after the ImmunoGen takeout, with a combined value of nearly $19bn, AbbVie thinks it has restocked its pipeline with future blockbusters to drive post-Humira growth.
Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT
Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.
Schizophrenia, Depression And Neuropathy: What’s Coming In 2024
The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem.